Agape ATP Corp (ATPC) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2024. Agape ATP Corp is a Nevada corporation operating primarily in the Health and Wellness industry in Malaysia, Hong Kong, and the U.S. The company supplies health supplements, wellness programs, and complementary health therapies. In 2024, the company expanded into renewable energy via a wholly-owned subsidiary, ATPC Green Energy Sdn. Bhd. (AGE). The company executed a 1-for-20 reverse stock split effective August 30, 2024; all share and per-share data in this summary reflect this adjustment.
Key Financial Metrics (Nine Months Ended Sept 30, 2024)
| Metric | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Revenue | $962,971 | $1,040,017 |
| Gross Profit | $581,166 | $683,142 |
| Gross Margin | 60.4% | 65.7% |
| Net Loss | $(1,659,449) | $(1,138,259) |
| Net Loss Attributable to ATPC | $(1,662,035) | $(1,127,555) |
| Loss Per Share (Basic/Diluted) | $(0.43) | $(0.30) |
| Cash and Cash Equivalents | $2,719,033 | $311,659 (End of Period 2023) |
| Total Assets | $3,963,694 | $5,744,494 (Dec 31, 2023) |
| Total Liabilities | $1,200,069 | $1,363,631 (Dec 31, 2023) |
| Working Capital | $2,452,343 | $4,113,614 (Dec 31, 2023) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 7.4% ($77,046) compared to the prior year. This was driven by a 70.1% drop in network marketing revenue ($223,271 decrease) due to a limited product range. Conversely, revenue from complementary health therapies increased by 17.7% ($127,821 increase) as post-pandemic demand for preventive care grew.
- Margin Compression: Gross margin declined from 65.7% to 60.4%. This was attributed to lower margins in the network marketing segment and varying margins in health therapies.
- Expense Increase: Operating expenses rose 27.2% to $2.3 million. General and Administrative (G&A) expenses increased by 38.5% ($598,647), primarily due to salaries for executive and independent directors, professional fees, and Nasdaq listing fees. Commission expenses dropped 66.3% in line with lower network marketing sales.
- Cash Flow: Net cash used in operating activities increased significantly to $2.08 million (from $995k in 2023), driven by the net loss and a $329,898 increase in prepayments and deposits.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management is diversifying into renewable energy through ATPC Green Energy to ensure sustainable growth. The company continues to focus on the "ATP Zeta Health Program" and complementary therapies.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2024. Material weaknesses were identified, including insufficient full-time accounting personnel and a lack of a functional internal audit department. Remediation plans include hiring additional staff and establishing formal accounting policies, with full implementation anticipated by mid-2025.
- Risks:
- Concentration Risk: One related-party vendor (CTA Nutriceuticals) accounted for approximately 63.4% of total purchases for the nine months ended Sept 30, 2024.
- Liquidity: While the company holds significant cash ($2.7M), it has an accumulated deficit of $8.7 million and continues to operate at a loss.
- Foreign Exchange: The company operates in Malaysia and Hong Kong but reports in USD, exposing it to currency fluctuation risks.
- Contingencies: No material legal proceedings or commitments were disclosed.
Key Facts for Investor Verification
- Reverse Stock Split: Verify the impact of the 1-for-20 reverse split on share ownership and trading liquidity.
- Related Party Transactions: Review the significant reliance on related-party vendors (CTA Nutriceuticals) for over 60% of purchases and the nature of these relationships.
- Internal Control Weaknesses: Assess the timeline and feasibility of the remediation plan for material weaknesses in financial reporting controls.
- Revenue Mix Shift: Monitor the sustainability of the decline in network marketing revenue versus the growth in complementary health therapies.
- Cash Burn Rate: Evaluate the runway provided by current cash reserves ($2.7M) against the current operating cash burn rate (~$2M per 9 months).